Setpoint Medical Corporation news
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapies for chronic autoimmune diseases, today announced the appointment of Amy Derosier as Vice President of Clinical Affairs.
“Amy’s extensive experience in successfully designing and executing clinical trials for novel medical devices complements that of our CMO, Dr. David Chernoff, who has extensive experience in rheumatology clinical research. Her leadership and partnership with Dr. C
Runway Growth Capital LLC (“Runway”), a leading provider of growth loans to both venture and non-venture backed companies seeking an alternative to raising equity, today announced the close of a senior secured term loan of $35 million to SetPoint Medical (“SetPoint”), a Valencia,
SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that the American Institute for Biological and Medical Engineering (AIMBE) has elected Murthy Simhambhatla, PhD, to the AIMBE College of Fellows for “outstanding contributions as a medical technology innovator and business leader, advancing health for millions of patients around the world.”
The College of Fellows is comprised of the top two
SetPoint Medical, Inc. today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel bioelectronic device for patients with rheumatoid arthritis (RA) who have incomplete response to, or are intolerant to multiple biologic drugs. The Company is developing its platform for the treatment of chronic, inflammation-mediated autoimmune diseases, and is initially focused on the treatment of RA as a potentially effic
Device reduced disease activity in 50% of patients who had failed multiple drug classes including Janus Kinase Inhibitors (JAKi)
SetPoint Medical, Inc. today announced that data from a first-in-human pilot trial that evaluated its proprietary Vagus Nerve Stimulation (VNS) microregulator in a cohort of patients with multi-drug refractory rheumatoid arthritis (RA) were published in The Lancet Rheumatology. The study